Lipum (publ), a clinical stage biopharmaceutical company focused on chronic inflammatory diseases, today announced its participation in the following upcoming events.

BioStock Investor Meeting, 20 September, Stockholm, Sweden

Redeye theme: Autoimmune and Inflammatory Disease, 3 October, Stockholm, Sweden

Småbolagsdagen i Lund, Aktiespararna, 9 October, Lund, Sweden

BIO-Europe, 6–8 November, München, Germany

Umeå på börsen, 14 November, Umeå, Sweden

Redeye Life Science Day, 23 November 2023, Stockholm, Sweden

Nordic Life Science Days, 29-30 November 2023, Copenhagen, Denmark

"I look forward to these meetings. Our clinical study of the drug candidate SOL-116 is ongoing and the industry meetings provide great opportunities to present our progress.", says CEO Einar Pontén.

Contacts
Einar Pontén, CEO
einar.ponten@lipum.se
+46 70 578 34 95
Web: www.lipum.se

About Us
Lipum AB (publ) is a clinical stage biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in clinical stage supported by solid data for rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum’s unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission.

Attachments
Lipum to participate in following upcoming

Lipum to participate in following upcoming